Involvement of FGFR4 Gene Variants on the Clinicopathological Severity in Urothelial Cell Carcinoma

Ming-Dow Tsay, Ming-Ju Hsieh, Chia-Yi Lee, Shian-Shiang Wang, Chuan-Shu Chen, Sheng-Chun Hung, Chia-Yen Lin and Shun-Fa Yang
Additional contact information
Ming-Dow Tsay: Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan
Ming-Ju Hsieh: Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan
Chia-Yi Lee: Department of Ophthalmology, Show Chwan Memorial Hospital, Changhua 500, Taiwan
Shian-Shiang Wang: Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan
Chuan-Shu Chen: Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan
Sheng-Chun Hung: Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan
Chia-Yen Lin: Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan
Shun-Fa Yang: Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan

IJERPH, 2019, vol. 17, issue 1, 1-9

Abstract: Fibroblast growth factor receptor 4 (FGFR4) plays a prominent role in cell proliferation and cancer progression. This study explored the effect of FGFR4 single-nucleotide polymorphisms (SNPs) on the clinicopathological characteristics of urothelial cell carcinoma (UCC). This study was conducted to survey the possible correlation of the polymorphism of FGFR4 to the risk and clinicopathologic characteristics of UCC. Four loci of FGFR4 (rs2011077 T > C, rs351855 G > A, rs7708357 G>A, and rs1966265 A > G) were genotyped via the TaqMan allelic discrimination approach in 428 UCC cases and 856 controls. The results indicated that UCC subjects who carried the SNP rs2011077 TC+CC genotypes were significantly related to a higher tumor stage (odds ratio (OR): 1.751, 95% confidence interval (CI): 1.078–2.846), primary tumor size (OR: 1.637, 95% CI: 1.006–2.662), and histopathologic grading (OR: 1.919, 95% CI: 1.049–3.511). Moreover, the SNP rs1966265 AG+GG genotypes were prominently related to a higher tumor stage (OR: 1.769, 95% CI: 1.082–2.891), primary tumor size (OR: 1.654, 95% CI: 1.011–2.706), and histopathologic grading (OR: 2.006, 95% CI: 1.096–3.674) compared to individuals with AA homozygotes. In conclusion, our data reveal association of FGFR4 polymorphisms with UCC clinicopathologic characteristics. FGFR4 polymorphisms may serve as a marker or therapeutic target in UCC development.

Keywords: fibroblast growth factor receptor 4; single-nucleotide polymorphism; urothelial cell carcinoma; tumor stage (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2019
References: View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.mdpi.com/1660-4601/17/1/129/pdf (application/pdf)
https://www.mdpi.com/1660-4601/17/1/129/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:17:y:2019:i:1:p:129-:d:301305

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().